Core Viewpoint - Zhaoke Ophthalmology-B (06622) has seen a stock price increase of over 5%, currently trading at 3.44 HKD, with a transaction volume of 1.707 million HKD, following the announcement of expanded partnerships for the commercialization of BRIMOCHOL™ PF in Singapore and Vietnam [1] Group 1: Partnerships and Commercialization - The company has expanded its partnership agreement with AFT Pharmaceuticals Limited to commercialize BRIMOCHOL™ PF in Singapore [1] - Zhaoke has also established a strategic partnership with Santen Pharmaceutical Co., Ltd. to commercialize the product in Vietnam [1] - AFT and Santen have been granted exclusive distribution rights in their respective markets, which include registration, import, promotion, distribution, marketing, and sales of BRIMOCHOL™ PF [1] Group 2: Product Information - BRIMOCHOL™ PF is a potential therapy for correcting near vision loss due to presbyopia, representing a core asset acquired through a partnership with Tenpoint Therapeutics, Ltd. [1] - The addition of AFT and Santen as commercialization partners marks the seventh and eighth partnerships for BRIMOCHOL™ PF, highlighting the company's commitment to global expansion [1]
港股异动 | 兆科眼科-B(06622)涨超5% 已扩大与AFT的伙伴协议 于新加坡商业化BRIMOCHOL PF